Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial. Oncotarget. 2019 Apr 19;10(29):2791-2792 Authors: Marmorino F, Falcone A, Cremolini C PMID: 31073370 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research